Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RIPK2 promotes colorectal cancer metastasis by protecting YAP degradation from ITCH-mediated ubiquitination

ABSTRACT: Colorectal cancer (CRC) is a leading cause of cancer death. RIPK2 is identified as a poor prognostic marker, promoting metastasis via bacterial invasion. High RIPK2-expressing tumor cells show enhanced invasiveness. This dataset comprises quantitative proteomic profiles of colorectal cancer (CRC) cells comparing non-targeting control (NC) and RIPK2-knockdown (KD) groups.

ORGANISM(S): Homo Sapiens

SUBMITTER: Chunzhao Yu

PROVIDER: PXD061372 | iProX | Mon Mar 03 00:00:00 GMT 2025

REPOSITORIES: iProX

ACCESS DATA

Json Xml

Publications

RIPK2 promotes colorectal cancer metastasis by protecting YAP degradation from ITCH-mediated ubiquitination.

Lu Chen C Liu Hongda H Liu Tianyu T Sun Sizheng S Zheng Yanan Y Ling Tao T Luo Xiagang X E Yiming Y Xu Yuting Y Li Jie J Liu Lei L Miao Lin L Liu Zhengxia Z Yu Chunzhao C

Cell death & disease 20250404 1

Colorectal cancer (CRC) is the second leading cause of cancer-related death worldwide, making the exploration of metastatic mechanisms crucial for therapeutic advancements. In this study, we identified receptor-interacting protein kinase 2 (RIPK2) as an independent risk factor for poor CRC prognosis. Single-cell RNA sequencing and spatial transcriptomics revealed that a tumor cell cluster with high RIPK2 expression exhibited enhanced metastatic potential, closely linked to bacterial invasion. In ...[more]

PMID: 40185717

Similar Datasets

Pharmacoproteomic characterisation of human colon and rectal cancer - CPTAC Full Proteomes

Project description:Most molecular cancer therapies act on protein targets but data on the proteome status of patients and cellular models are only beginning to emerge. Here, we profiled the proteomes of 65 colorectal cancer (CRC) cell lines to a depth of >10,000 proteins using mass spectrometry. Integration with proteomes of 90 CRC patients, as well as transcriptomes of 145 cell lines and 89 patients defined integrated CRC subtypes, highlighting cell lines representative of each tumour subtype. Modelling the responses of 52 CRC cell lines to 577 drugs as a function of proteome profiles enabled predicting drug sensitivity for cell lines and patients. Among many novel associations, MERTK was identified as a predictive marker for resistance towards MEK1/2 inhibitors and immunohistochemistry of 1,000 CRC tumours confirmed MERTK as a prognostic survival marker. We provide the proteomic and pharmacological data to the community to e.g. facilitate the design of innovative prospective clinical trials.

2017-11-23 | MSV000081739 | MassIVE

Pharmacoproteomic characterisation of human colon and rectal cancer - CRC65 Kinobeads

2017-11-23 | MSV000081735 | MassIVE

Pharmacoproteomic characterisation of human colon and rectal cancer - CRC65 Full Proteomes

2017-11-23 | MSV000081738 | MassIVE

Pharmacoproteomic characterisation of human colon and rectal cancer - CRC65 Kinobeads

2017-12-12 | PXD005355 | Pride

Pharmacoproteomic characterisation of human colon and rectal cancer - CRC65 Full Proteomes

2017-12-12 | PXD005354 | Pride

Pharmacoproteomic characterisation of human colon and rectal cancer - CPTAC Full Proteomes

2017-12-13 | PXD005353 | Pride

CAPG silencing promotes CRC cell apoptosis and ferroptosis via P53 pathway

Project description:Colorectal cancer (CRC) is the third most common cancer in the world and the second leading cause of cancer-related deaths. However, there are few effective therapeutic targets for colorectal cancer. Here, we report that Capping Actin Protein, Gelsolin Like (CAPG), a protein involved in actin related movement, is significantly overexpressed in human CRC tissues, and that expression levels are inversely correlated with overall survival. CAPG knockdown CRC cell lines inhibited cell proliferation, blocked cell cycle in G1 phase, increased apoptosis rate and promoted the occurrence of ferroptosis. RNA-seq data suggested that CAPG silencing promotes cell cycle arrest, apoptosis, and ferroptosis by activating the P53 pathway. Therefore, CAPG has potential to serve as a prognostic marker as well as a cancer therapy target in the future.

2023-06-11 | GSE234395 | GEO

Indraccolo_Notch3

Project description:Notch3 expression was analyzed in 20 patients suffering from colorectal carcinoma (CRC) and their corresponding colonic normal (NC) tissue.

2011-05-18 | E-MEXP-3188 | biostudies-arrayexpress

Aberrant promoter methylation and gene amplification in colorectal cancer

Project description:To identify new markers for colorectal cancer we scrutinized the methylation status by methyl-CpG immunoprecipitation followed by global methylation profiling on a CpG island microarray, as altered expression could drive genomic and chromosomal instability observed in these tumors. We show for the first time hypermethylation of MMP9, DNMT3A, and LIG4 in CRC which was confirmed in two independent ethnic CRC patients groups. Hypermethylation of the LIG4 promoter is a new mechanism to control ligase IV expression. It may represent a new epigenetic marker for colorectal cancer independent of known markers. Methylation profiling in 16 tumors of colorectal cancer patients compared to matched normal tissue of these patients

2013-12-31 | E-GEOD-47413 | biostudies-arrayexpress

microRNA expression profiling of human colorectal cancer cell lines: HRT-18 vs. Caco-2

Project description:MicroRNAs regulate the biological aggressiveness of colorectal cancer (CRC) cells and might serve as potential prognostic factors and therapeutic targets. In this study, we therefore globally profiled microRNAs associated with aggressive growth in CRC cells, in an attempt to identify novel prognostic biomarkers in CRC patients. In detail, two different CRC cell lines (Caco-2 and HRT-18) with completely different growth rates and different E-cadherin expression were profiled for differences in more than 1000 human microRNAs by using microarray technology.

2014-01-13 | GSE53095 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data